BioMS Medical invests in Spectral Diagnostics to advance treatment for sepsis
 

Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.

More...